Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies

Green, Larry L · 1999 · Journal of Immunological Methods

Abstract

The major impediment to the development of murine monoclonal antibodies (mAbs) for therapy in humans has been the difficulty in reducing their potential immunogenicity. XenoMouse¿trade mark omitted¿ mice obviate this problem while retaining the relative ease of generating mAbs from a mouse. XenoMouse strains include germline-configured, megabase-sized YACs carrying portions of the human IgH and Igkappa loci, including the majority of the variable region repertoire, the genes for Cmicro, Cdelta and either Cgamma1, Cgamma2, or Cgamma4, as well as the cis elements required for their function. The IgH and Igkappa transgenes were bred onto a genetic background deficient in production of murine immunoglobulin. The large and complex human variable region repertoire encoded on the Ig transgenes in XenoMouse strains support the development of large peripheral B cell compartments and the generation of a diverse primary immune repertoire similar to that from adult humans. Immunization of XenoMouse mice with human antigens routinely results in a robust secondary immune response, which can ultimately be captured as a large panel of antigen-specific fully human IgGkappa mAbs of sub-nanomolar affinities. Monoclonal antibodies from XenoMouse animals have been shown to have therapeutic potential both in vitro and in vivo, and appear to have the pharmacokinetics of normal human antibodies based on human clinical trials. The utility of XenoMouse strains for the generation of large panels of high-affinity, fully human mAbs can be made available to researchers in the academic and private sectors, and should accelerate the development and application of mAbs as therapeutics for human disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0022-1759(99)00137-4

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Griffiths, A.D., Hoogenboom, H.R., 1993. Building an in vitro immune system: human antibodies from phage display libraries. In: Nottingham, C.M. (Ed.), Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Application in Man. Academic Titles, p. 45.

Cited by

See all 233

Metadata

Authors
Green, L. L.
Corresponding author
Green, Larry L
Venue
Journal of Immunological Methods
Publisher
Elsevier BV
Published
1999-12
Volume
231
Issue
1-2
Pages
11-23
ISSN
0022-1759 (ISSN-L)
OpenAlex
W1992767687
Cited by
229
References
50
Citations by year
2025: 4 · 2024: 3 · 2023: 4 · 2021: 4 · 2020: 6 · 2019: 10 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 8 · 2014: 4 · 2013: 17 · 2012: 13
FWCI
7.35
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of Immunological Methods (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Animal Genetics and Reproduction
  • Health Sciences › Medicine › Surgery › Xenotransplantation and immune response
Keywords
humanized mice, monoclonal antibodies, therapeutic antibodies, immunogenicity, B cell development, secondary immune response, pharmacokinetics, antibody affinity
MeSH terms
Animals, Antibodies, Monoclonal, Antibody Affinity, B-Lymphocytes, Genetic Engineering, Humans, Immunoglobulin G, Immunoglobulin M, Immunoglobulin Variable Region, Protein Engineering, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. https://app.cochat.ai/papers/10.1016/s0022-1759(99)00137-4
The paper
Green, L. L. (1999). Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. Journal of Immunological Methods. https://doi.org/10.1016/s0022-1759(99)00137-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.